← ANALYST RATINGS · TIPRANKS
Becton Dickinson (BDX): analyst forecast and price target
Analyst consensus
Moderate Buy4 Buy5 Hold1 Sell
Ratings of 10 analysts in the last 3 months12-month forecast
Based on 10 price targets given in the last 3 months, the average target is $192, the highest $210, the lowest $165. The average is 0.0% from the last price of $192.
Analyst ratings 14
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Medical - Instruments and SuppliesxAI Grok-3 | TipRanks - xAI | $192 → $216+12.5% | Buy | +12.6% | Reiterated | 17.10.26on TipRanks Oct 16 23:06 | — | |
| AI DeepSeek Medical - Instruments and SuppliesDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $183 → $208+13.7% | Hold | +8.5% | Reiterated | 17.10.26on TipRanks Oct 16 23:06 | — | |
| AI OpenAI Medical - Instruments and SuppliesOpenAI 5.2 | TipRanks - OpenAI | $182 → $208+14.3% | Hold | +8.5% | Reiterated | 17.10.26on TipRanks Oct 16 23:06 | — | |
| AI Anthropic Medical - Instruments and SuppliesAnthropic Opus-4.5 | TipRanks - Anthropic | $172 → $198+15.1% | Hold | +3.3% | Reiterated | 17.10.26on TipRanks Oct 16 23:06 | — | |
| AI Google Medical - Instruments and SuppliesGemini 3-pro | TipRanks - Google | $188 → $216+14.9% | Buy | +12.6% | Reiterated | 17.10.26on TipRanks Oct 16 23:06 | — | |
| Matt Miksic★★★★★★★★★★#2645 · hits 55% · avg +3.9% | Barclays | $165 | Sell | −14.0% | Initiated | 07.10.26on TipRanks 03:55 | +0.2%next day +1.9% · 5 days +5.8% | ↗ |
| Travis Steed★★★★★★★★★★#3596 · hits 53% · avg +3.0% | Bank of America Securities | $200 | Hold | +4.3% | Reiterated | 06.10.26on TipRanks Oct 7 06:45 | −0.8%next day +0.2% · 5 days +4.1% | ↗ |
| Joanne Wuensch★★★★★★★★★★#3684 · hits 55% · avg +2.3% | Citi | $208 | Buy | +8.5% | Reiterated | 05.10.26on TipRanks 07:21 | +1.5%next day −0.8% · 5 days +4.1% | ↗ |
| Name not given | — | $190 | Hold | −0.9% | Reiterated | 01.10.26on TipRanks Oct 2 21:45 | −0.7%next day −1.5% · 5 days +1.3% | ↗ |
| Matthew Taylor★★★★★★★★★★#1367 · hits 55% · avg +7.2% | Jefferies | $210 | Buy | +9.5% | Reiterated | 08.09.26on TipRanks 09:07 | −2.5%next day +1.4% · 5 days +5.5% | ↗ |
| AI PerPlexity Medical - Instruments and SuppliesPerPlexity SonarPro | TipRanks - PerPlexity | $194 → $193−0.5% | Hold | +0.7% | Reiterated | 20.08.26on TipRanks Aug 19 23:06 | — | |
| Josh Jennings★★★★★★★★★★#3537 · hits 46% · avg +3.0% | TD Cowen | $182 | Hold | −5.1% | Assigned | 17.08.26on TipRanks 05:36 | −0.2%next day 0.0% · 5 days +5.9% | ↗ |
| Patrick Wood★★★★★★★★★★#10768 · hits 50% · avg −2.1% | UBS | $190 → $205+7.9% | Buy | +6.9% | Assigned | 12.08.26on TipRanks 08:00 | +0.9%next day −1.6% · 5 days +2.6% | ↗ |
| Rick Wise★★★★★★★★★★#7800 · hits 51% · avg +0.1% | Stifel Nicolaus | $195 | Buy | +1.7% | Reiterated | 11.08.26on TipRanks Aug 12 22:05 | +1.3%next day +0.9% · 5 days +0.1% | ↗ |
| Robbie Marcus★★★★★★★★★★#1974 · hits 51% · avg +6.5% | J.P. Morgan | $188 | Hold | −2.0% | Reiterated | 10.08.26on TipRanks Aug 11 08:07 | +1.6%next day +1.3% · 5 days +1.4% | ↗ |
| Jason Bednar★★★★★★★★★★#11450 · hits 46% · avg −2.5% | Piper Sandler | $161 → $175+8.7% | Hold | −8.7% | Reiterated | 07.08.26on TipRanks 08:01 | −0.7%next day +1.6% · 5 days +3.3% | ↗ |
| Vijay Kumar★★★★★★★★★★#2375 · hits 54% · avg +4.8% | Evercore ISI | $190 → $180−5.3% | Buy | −6.1% | Reiterated | 06.07.26on TipRanks 08:50 | −2.5%next day +1.0% · 5 days −0.8% | ↗ |
| David Roman★★★★★★★★★★#3715 · hits 53% · avg +5.3% | Goldman Sachs | $167 | Hold | −12.9% | Initiated | 10.04.26on TipRanks 13:15 | −0.7%next day −0.2% · 5 days −1.7% | ↗ |
| David Toung★★★★★★★★★★#1098 · hits 63% · avg +9.1% | Argus Research | $230 → $180−21.7% | Buy | −6.1% | Assigned | 20.03.26on TipRanks Mar 23 09:25 | −0.1%next day +0.3% · 5 days +2.5% | ↗ |
| Larry Biegelsen★★★★★★★★★★#2729 · hits 53% · avg +3.8% | Wells Fargo | $184 → $157−14.7% | Hold | −18.1% | Reiterated | 10.02.26on TipRanks 07:00 | +5.6%next day +5.2% · 5 days +7.3% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Becton Dickinson
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $193 at a price of $179 (+8.0%); now: $192 at $192 (0.0%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 9 | 5 | 6 | 9 | 10 | 8 |
| Hold | 11 | 11 | 9 | 11 | 10 | 10 |
| Sell | 0 | 0 | 0 | 0 | 0 | 1 |
Earnings and sales forecast
Next report: 05.11.26 (Q4 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $4.07 (from $4.03 to $4.12). Last quarter: $3.23.
Sales
Next quarter’s sales estimate — $5.1B (from $5.1B to $5.2B). Last quarter: $5.0B.
Best top-analyst consensus in the sector · Healthcare
About Becton Dickinson
- CEO: Thomas E. Polen Jr.
- Employees: 72,000
- 1 Becton Drive, Franklin Lakes, NJ, 07417-1880, US
- www.bd.com
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological
Data from the stock’s TipRanks forecast page, read 40 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗